(:NK)

Nov 18, 2021 09:01 am ET
Haeggquist & Eck, LLP Announces Investigation Regarding Whether PennyMac Required Home Owners to Purchase Excess Homeowners’ Insurance for Home Loans and Home Loan Refinancing
Haeggquist & Eck, LLP, a leading consumer rights litigation firm, is investigating whether lending practices by PennyMac Loan Services, LLC (“PennyMac”) violated California law by requiring home owners to purchase excess homeowners’ insurance for home loans and/or home loan refinancing.
Mar 09, 2021 04:15 pm ET
ImmunityBio and NantKwest Complete Merger
ImmunityBio, Inc. and NantKwest, Inc. (
Mar 08, 2021 04:30 pm ET
Stockholders of NantKwest Approve Merger With ImmunityBio
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeu
Feb 26, 2021 03:00 am ET
SHAREHOLDER ALERT: Barr Law Group Investigating NK, IQDNX, JELD, and MDXG; Shareholders are Encouraged to Contact the Firm
National law firm Barr Law Group is investigating the actions of the officers and board of directors of NantKwest, Inc., Infinity Q Diversified Alpha Fund, JELD-WEN Holding, Inc., and MiMedx Group, Inc.   If you are a current owner of shares of any...
Feb 24, 2021 07:26 pm ET
All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote “FOR” the Pending Merger With ImmunityBio
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”), Glass, Lewis & Co., LLC (“Glass Lewis”), and Egan-Jones Proxy Services (“Egan-Jones”) have recommended NantKwest stockholders vote “FOR” the pending merger with ImmunityBio.
Feb 24, 2021 09:00 am ET
ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors
ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to the company’s board of directors, effective immediately.
Feb 23, 2021 07:00 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - CTB, PBCT, HMSY, NK, SPWH
NEW YORK, Feb. 23, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Feb 20, 2021 05:35 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Merger Investigation
Rigrodsky Law, P.A. announces that it is investigating: NantKwest, Inc. (NASDAQ GS: NK) regarding possible breaches of fiduciary duties and other violations of law related to NantKwest’s agreement to merge with ImmunityBio, Inc. To learn more...
Feb 17, 2021 10:40 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, CLGX, SYNC, NK; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: MDC Partners Inc. (NASDAQ: MDCA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to...
Feb 16, 2021 09:00 am ET
Feb 13, 2021 11:06 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, FFG, ALXN, NK, HLIX; Shareholders Are Encouraged to Contact the Firm
NEW YORK, Feb. 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Feb 12, 2021 08:00 pm ET
SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Feb 11, 2021 06:13 pm ET
ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity
ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have received FDA authorization to expand Phase I testing of a bivalent hAd5 T-cell COVID-19 vaccine. The FDA authorized the expansion of a currentl
Feb 06, 2021 10:52 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates NK, ALXN, CATM, CGIX, MTSC; Shareholders Are Encouraged to Contact the Firm
NEW YORK, Feb. 6, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Feb 04, 2021 06:57 pm ET
SHAREHOLDER ALERT: Barr Law Group Investigating NK, PS, JELD, and APLT; Shareholders are Encouraged to Contact the Firm
National law firm Barr Law Group is investigating the actions of the officers and board of directors of NantKwest, Inc., Pluralsight, Inc., JELD-WEN Holding, Inc., and Applied Therapeutics, Inc.  If you are a current owner of shares of any of these...
Feb 02, 2021 04:54 pm ET
NANTKWEST INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of NantKwest, Inc. - NK
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of NantKwest, Inc. (NasdaqGS: NK) with ImmunityBio, Inc. pursuant to which NantKwest shareholders will end up owning just 28% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Feb 02, 2021 10:37 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates VIE, SMTX, NK, OBLN; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Viela Bio, Inc. (NASDAQ: VIE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to...
Jan 30, 2021 05:04 pm ET
Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders Are Encouraged to Contact the Firm - NHLD, COHR, MTSC, NK, PNM
NEW YORK, Jan. 30, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:
Jan 28, 2021 09:00 am ET
ImmunityBio Announces Positive Phase 2 Results Showing That Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer
ImmunityBio, Inc., a privately held immunotherapy company, today announced the presentation of encouraging data in non-small cell lung cancer (NSCLC) from the company’s ongoing Phase 2b study, QUILT-3.055 (ClinicalTrials.gov: NCT03228667) at the International Association for the Study of Lung Cancer (IASCL)’s 2020 World Conference on Lung Cancer, Singapore, being held virtually January 28 – 31, 2021.
Jan 28, 2021 08:00 am ET
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates NHLD, COHR, ALSK, NK; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: National Holdings Corporation (NASDAQ: NHLD) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Jan 21, 2021 04:09 pm ET
MERGER INVESTIGATION: Halper Sadeh LLP Investigates RP, BPFH, ALSK, NK, ANH; Shareholders Are Encouraged to Contact the Firm
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jan 21, 2021 01:17 pm ET
RM LAW Announces Investigation of NantKwest, Inc.
BERWYN, Pa., Jan. 21, 2021 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to ImmunityBio, Inc.
Jan 21, 2021 12:56 pm ET
INVESTIGATION ALERT: Nationally Ranked Shareholder Rights Law Firm Labaton Sucharow is Investigating NantKwest, Inc. (NASDAQ: NK) for Potential Securities Violations and Breach of Fiduciary Duty
Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, is investigating potential securities violations and breach of fiduciary duty against cellular therapies company NantKwest, Inc. (NASDAQ: NK) in connection with its acquisition of ImmunityBio, a privately held company.
Jan 19, 2021 08:01 am ET
NK INVESTOR ALERT: Kaskela Law LLC Announces Stockholder Investigation of NantKwest, Inc.
Kaskela Law LLC announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ: NK) on behalf of the company’s shareholders. On December 21, 2020, NantKwest announced that it had entered into an agreement to merge with ImmunityBio, a...
Jan 18, 2021 12:00 am ET
ALERT: Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm – RP, BPFH, NK, SPWH
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: RealPage, Inc. (NASDAQ: RP) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its...
Jan 15, 2021 08:00 pm ET
SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, Jan. 15, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Jan 14, 2021 03:43 pm ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ALXN, CHNG, RP, RNET, MDCA, NK; Shareholders Are Encouraged to Contact the Firm
NEW YORK, Jan. 14, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jan 14, 2021 08:31 am ET
Thinking about buying stock in Express, Nantkwest, Gevo, Canopy Growth Corp, or Chembio Diagnostics?
NEW YORK, Jan. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXPR, NK, GEVO, CGC, and CEMI.
Jan 13, 2021 09:00 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of NK, RNET, HMSY, and QEP Mergers
Rigrodsky Law, P.A. announces that it is investigating: NantKwest, Inc. (NASDAQ GS: NK) regarding possible breaches of fiduciary duties and other violations of law related to NantKwest’s agreement to merge with ImmunityBio, Inc. To learn more...
Jan 13, 2021 06:01 pm ET
NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
The early collaborative Cancer Moonshot trials involved the combination of cell therapy and immunotherapeutics from multiple biotech and pharmaceutical companies, including NantKwest, ImmunityBio, Celgene, and Pfizer. These trials explored the hypothesis that by activating the patient’s own immune system, a paradigm change in cancer therapy could evolve to eradicate cancer cells without high-dose chemotherapy. From 2017 to 2020, multiple QUILT clinical trials exploring this combination of cell therapy, immunomodulating antibodies, adenovirus-based cancer vaccines, and low-dose chemotherapy pro
Jan 13, 2021 02:19 am ET
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates RNET, HMSY, NK, PRGX; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: RigNet, Inc. (NASDAQ: RNET) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to...
Jan 07, 2021 03:18 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CHNG, BPFH, RP, MDCA, NK; Shareholders Are Encouraged to Contact the Firm
NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jan 06, 2021 09:00 am ET
NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executive Chairman of the Board of Directors, will participate in the 39th Annual J.P. Morgan Healthcare Conference. He will make a formal presentation and answer questions at 5:20 a.m. Pacific Time (8:20 a.m. Eastern Time) on Wednesday, January 13, 2021. Dr. Soon-Shiong will discuss NantKwest’s previously announced agreement to combine in a stock-for-stock transaction with ImmunityBio, Inc. The combination, which is expected to close in
Jan 05, 2021 10:18 pm ET
Jan 05, 2021 05:36 pm ET
NANTKWEST ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of NK and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of NantKwest, Inc. (NASDAQ: NK) breached their fiduciary duties or violated the federal securities laws...
Dec 30, 2020 10:09 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers – WTRE, ARA, RESI, NK
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Watford Holdings Ltd. (NASDAQ: WTRE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Dec 29, 2020 07:58 pm ET
Dec 29, 2020 06:40 pm ET
NANTKWEST INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of NantKwest, Inc. - NK
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of NantKwest, Inc. (NasdaqGS: NK) with ImmunityBio, Inc. pursuant to which NantKwest shareholders will end up owning just 28% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Dec 28, 2020 07:20 pm ET
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - PRGX, STND, NK, EIDX, ARA
NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 28, 2020 11:22 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of NantKwest, Inc. (NK) and Encourages Shareholders to Contact the Firm
Kaskela Law LLC announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ: NK) on behalf of the company’s shareholders. NantKwest shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585,...
Dec 28, 2020 08:07 am ET
NANTKWEST (NK) SHAREHOLDER ALERT - Andrews & Springer LLC Is Seeking More Cash for Shareholders of NantKwest, Inc.
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of NantKwest, Inc. (NASDAQGS: NK)...
Dec 24, 2020 10:08 am ET
NantKwest Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of NantKwest, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NK
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of NantKwest, Inc. (NASDAQ:NK) and ImmunityBio is fair to NantKwest shareholders. Under the terms of the agreement, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned. Upon completion of the transaction, ImmunityBio shareholders will own approximately 72% of the combined company and NantKwest shareholders will own approximately 28% of the combined company.
Dec 23, 2020 08:00 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of NantKwest, Inc. - NK
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating NantKwest, Inc. ("NK" or the "Company") (NK) relating to its proposed merger with ImmunityBio. Under the terms of the agreement, ImmunityBio shareholders will receive 0.8190 shares of NantKwest per share they own.
Dec 23, 2020 05:58 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of NantKwest, Inc. Merger
Rigrodsky & Long, P.A. announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ GS: NK) regarding possible breaches of fiduciary duties and other violations of law related to NantKwest’s agreement to merge with ImmunityBio, Inc. To...
Dec 22, 2020 10:02 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of NantKwest, Inc. – NK
Kaskela Law LLC announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ: NK) on behalf of the company’s shareholders. NantKwest shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 –...
Dec 21, 2020 06:56 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates NantKwest, Inc.
NEW YORK, Dec. 21, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK) in connection with the Company's proposed merger with ImmunityBio, a privately-held late stage immunotherapy company.  Under the terms of the merger agreement, NantKwest will acquire ImmunityBio through a reverse merger pursuant to which, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned.  Upon co
Dec 21, 2020 07:30 am ET
Thinking about buying stock in Nantkwest, RealPage, Aerojet Rocketdyne, AIM ImmunoTech, or Corbus Pharmaceuticals?
NEW YORK, Dec. 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NK, RP, AJRD, AIM, and CRBP.
Dec 21, 2020 06:05 am ET
 ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate
ImmunityBio, Inc., a privately-held immunotherapy company, today announced positive data from the first cohort of a pivotal Phase 2/3 trial (QUILT 3.032) for non-muscle invasive bladder cancer in high risk carcinoma in situ (CIS) disease. The data showed 51 out of 71 evaluable patients (72%) had a complete response (at any time) to intravesical BCG plus N-803 (Anktiva), with 59% probability of these patients maintaining a complete response for at least 12 months, with a median duration of complete response of 19.2 months to date.
Dec 21, 2020 06:05 am ET
ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company
ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have entered into an agreement to merge in a stock-for-stock transaction. The combination will create a leading immunotherapy and cell therapy company focused on oncology and infectious disease.
Dec 11, 2020 08:31 am ET
Thinking about buying stock in Nantkwest, Ampio Pharmaceuticals, Arbutus Biopharma, Xeris Pharmaceuticals, or iBio Inc?
NEW YORK, Dec. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NK, AMPE, ABUS, XERS, and IBIO.
Dec 10, 2020 09:48 pm ET
ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates
ImmunityBio, a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. The study, sponsored by the Biomedical Advanced Research & Development Authority (BARDA), provides further evidence supporting the company’s use of a second-generation adenoviral vector that induces the immune system to both activate T cells and generate antibodies against multiple viral targets—blocking virus replication and clearing existing infection.
Nov 23, 2020 09:00 am ET
ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
ImmunityBio, a privately-held immunotherapy company, today announced the publication in Cancer Immunology, Immunotherapy of preclinical data demonstrating that ImmunityBio’s Anktiva™ (IL-15 superagonist also known as N-803) improves interferon-gamma (IFN-γ) production and killing of tumor of cells in vitro and in vivo by CD34+ progenitor-derived natural killer (NK) cells. Anktiva is currently being evaluated in late-stage clinical trials in combination with NantKwest’s (
Nov 18, 2020 09:15 am ET
NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare Conference
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32nd Annual Piper Sandler Healthcare conference, which takes place December 1-3, 2020. NantKwest Executive Chairman Patrick Soon-Shiong, M.D., and Chief Executive Officer Rich Adcock will participate in institutional investor meetings on Tuesday, December 1; meetings may be requested through Piper Sandler.
Nov 10, 2020 07:00 am ET
ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study
ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have administered their second-generation bivalent, human adenovirus (hAd5) COVID-19 vaccine candidate in a Phase 1 trial with no serious adverse events (SAE) reported in the low dose cohort, safety is ongoing for the high dose cohort. The trial, being conducted at Hoag Hospital in Newport Beach, California, enrolled 20 volunteers across two dose levels and the subject screening for the Phase I expansion cohort is ongoing.
Nov 09, 2020 09:00 am ET
ImmunityBio’s hAd5 COVID-19 Vaccine Candidate Stimulates Memory T-Cell Recall in Patients Infected with SARS-CoV-2
ImmunityBio, Inc. a privately-held, clinical-stage immunotherapy company, today announced positive study results for their human Ad5 (hAd5) COVID-19 vaccine candidate, which shows memory T-cell recall from patients previously infected with SARS-CoV-2 virus. The ability to stimulate SARS-CoV 2 specific T-cells, which recognize the N and S proteins, is a crucial part of the novel design of ImmunityBio’s vaccine candidate. The antibody- and T cell-based vaccine seeks both to provide protection for the uninfected population and also the potential to clear virally infected cells in infected subject
Oct 26, 2020 04:15 pm ET
NantKwest Names Richard Adcock Chief Executive Officer
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today appointed healthcare industry veteran with proven operational skills Richard Adcock as its Chief Executive Officer, effective immediately. Adcock brings extensive leadership experience to NantKwest as the company advances rapidly in the development of natural killer cell-based immunotherapies for cancer and serious infectious diseases. Rich will assume the role of CEO from Dr. Patrick Soon-Shiong, who will become Executive Chairman of the Board. Dr. Soon-Shiong remains the largest shareholder
Oct 21, 2020 05:06 pm ET
ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation COVID-19 Vaccine Candidate Delivering Both Spike and Nucleocapsid of SARS-CoV-2
ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that the first patient has been dosed in the Phase 1 clinical trial of hAd5-COVID-19, a novel COVID-19 vaccine candidate that targets the inner nucleocapsid (N) and the outer spike (S) protein, engineered to activate both T cells and antibodies against the coronavirus (SARS-CoV-2). This is a novel COVID vaccine that uses a second-generation adenovirus that delivers multiple proteins of the SARS-CoV-2 with the potential for long
Oct 15, 2020 06:00 am ET
FDA Authorizes Phase 1 Trial of ImmunityBio’s Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both T Cell and Antibody Immunity
ImmunityBio, Inc., a privately-held immunotherapy company, today announced it has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2). These dual constructs (bivalent sequences) of SARS-CoV-2 offer the potential for the hAd5 vaccine to provide recipients with durable, long-term cell-mediated immunity w
Oct 06, 2020 04:05 pm ET
NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All Approved Standards of Care
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced they have added a third cohort to their ongoing Phase 2 trial of a novel immunotherapy for locally advanced or metastatic pancreatic cancer. The third cohort enables pancreatic cancer patients who have failed all approved standards of care to participate in the trial.
Sep 21, 2020 09:00 am ET
NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6, 2020 at 12:50 PM ET.
Sep 10, 2020 09:00 am ET
Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH
Brink Biologics, Inc. (“Brink”), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwest’s proprietary off-the-shelf NK-92® natural killer cells in certain fields, announces the licensing of its next-generation natural killer-based bioanalytical testing solution to Fresenius Kabi SwissBioSim GmbH (“Fresenius”), a Switzerland-based global healthcare company focusing on autoimmune diseases and oncology.
Aug 24, 2020 09:00 am ET
NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics
NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately held immunotherapy company, today announced the signing of a definitive agreement to jointly develop, manufacture, market, and commercialize therapeutics and vaccines for combating the COVID-19 pandemic.
Jun 29, 2020 04:05 pm ET
NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock (4,811,500 shares at a price to the public of $9.50 per share and 3,710,000 shares at a price of $12.12 per share to NantKwest’s chairman, chief executive officer and principal stockholder, Dr. Patrick Soon-Shiong), which includes 1,111,500 shares sold upon full exercise of the underwriters’ option to purchase additional shares at a public offering price of $9.
Jun 25, 2020 01:01 am ET
NantKwest Announces Pricing of Public Offering of Common Stock
NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock (3,700,000 shares at a price to the public of $9.50 per share and 3,710,000 shares at a price of $12.12 per share to NantKwest’s chairman, chief executive officer and principal stockholder, Dr. Patrick Soon-Shiong). The aggregate gross proceeds from the offering are expected to be approximately $80.1 million, before deducting the underwriting discounts and commissions and offering e
Jun 24, 2020 04:15 pm ET
NantKwest Announces Proposed Public Offering of Common Stock
NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, NantKwest expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering. NantKwest intends to use the net proceeds of the offering for clinical development, manufacturing, upgrades to its facilities and equipment, and other working capital, capital expenditur
Jun 22, 2020 09:31 am ET
Thinking about buying stock in Virgin Galactic, Miragen Therapeutics, Nantkwest Inc, Agenus Inc, or Norwegian Cruise Line?
NEW YORK, June 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPCE, MGEN, NK, AGEN, and NCLH.
Jun 10, 2020 09:00 am ET
 NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Lin
NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the publication of two peer-reviewed manuscripts in the Journal of Immunotherapy of Cancer. These invitro and in-vivo studies, conducted in collaboration with the National Cancer Institute pursuant to a Cooperative Research and Development Agreement, support the mechanism and functionality of NantKwest’s clinical-stage engineered natural killer (NK) cell lines, haNK® and first-in-class PD-L1 t-haNKTM, as effecting anti-tumor activity in treatment-r
May 27, 2020 12:00 pm ET
ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine 
NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced ImmunityBio has been selected to participate in Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021. Efforts will focus on the development, testing, and large-scale manufacturing of ImmunityBio’s COVID-19 human adenovirus vaccine (hAd5) candidate. This is the first vaccine designed to deliver both Spike (S) and Nucleocapsid (N) DNA, offer
May 26, 2020 09:30 am ET
NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference
NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET.
May 19, 2020 08:00 am ET
Be The Match BioTherapies and NantKwest Announce Collaboration to Accelerate Development of Cell Therapy to Prevent COVID-19 Deaths
Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and NantKwest (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing t
May 18, 2020 08:30 am ET
NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients
NantKwest, Inc. (NASDAQ: NK) today announced it has received authorization from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with BM-Allo.MSC, an allogeneic mesenchymal stem cell (MSC) product derived from human bone marrow. NantKwest has entered into an agreement with the National Marrow Donor Program (Be the Match) to provide donor material and has developed automated proprietary methods to expand and generate multiple dose forms utilizing a modular, closed system (
May 14, 2020 04:25 pm ET
NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer
NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of their combination immunotherapy: NantKwest’s PD-L1 t-haNK, ImmunityBio’s N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer.
Apr 29, 2020 04:15 pm ET
NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference
NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2020 at 4:20 pm ET.
Apr 14, 2020 08:30 am ET
NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter
NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., clinical-stage immunotherapy companies within the NantWorks family of companies, today announced they are in active discussions with the U.S. Food and Drug Administration (FDA) for vaccines and therapeutics to combat COVID-19.
Mar 19, 2020 08:00 am ET
NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells
NantKwest, Inc. (Nasdaq: NK), a next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer and infectious diseases, today announced dosing of the first patient in a Phase 2 trial for second- and third-line Merkel cell carcinoma (MCC) in patients who are refractory to immune checkpoint inhibitors. The trial will evaluate the Company’s first-in-class, off-the-shelf CD16-targeted natural killer (haNK) cells in combination with ImmunityBio’s IL-15 superagonist N-803 and Avelumab.
Jan 16, 2020 08:00 am ET
Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference
Patrick Soon-Shiong, M.D., Chairman and CEO of NantKwest, Inc. and ImmunityBio, Inc. presented an update of the Cancer Breakthrough 2020 Initiative (the “Initiative”) and findings on the preliminary safety and early signals of efficacy in Phase 1 and 2 trials for multiple tumor types at the 2020 J.P. Morgan Healthcare Conference on January 14, 2020 in San Francisco.
Jan 14, 2020 08:00 am ET
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15
NantKwest Inc., (Nasdaq: NK), a clinical-stage natural killer cell-based therapeutics company, today announced results from their Phase 1 trial investigating a novel, first-in-human immunotherapy consisting of NantKwest’s off-the-shelf, PD-L1 tumor-targeted NK cells (NCT04050709). In addition, NantKwest and ImmunityBio, Inc., a privately held immunotherapy company, reported on a compassionate use expanded access IND combining the PD-L1-targeted NK cell with ImmunityBio’s IL-15 fusion protein (N-803) in a patient with metastatic pancreatic cancer who had relapsed after prior standard of care th
Dec 16, 2019 07:00 am ET
NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in Refractory T
NantKwest Inc. (Nasdaq: NK), a clinical-stage natural killer cell-based therapeutics company, and ImmunityBio, a privately held immunotherapy company, today announced results from their Phase 1b trial investigating a novel, first-in-human immunotherapy protocol consisting of NantKwest’s off-the-shelf, antibody-targeted NK cells (haNK) combined with ImmunityBio’s IL-15 superagonist (N-803), low-dose metronomic chemoradiation therapy, adenoviral and yeast tumor-associated antigen vaccines (MUC1, brachyury, CEA) and a PD-L1 checkpoint inhibitor in patients with metastatic triple negative breast c
Dec 02, 2019 04:05 pm ET
NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers
NantKwest, Inc. (Nasdaq: NK), a clinical-stage natural killer cell-based therapeutics company, today announced promising safety data generated from the first six patients in its QUILT-3.064 trial. The first-in-human study evaluated the safety and preliminary efficacy of the Company’s first-in-class, tumor-targeted PD-L1.t-haNK cell therapy in patients with locally advanced or metastatic solid tumors.
Nov 27, 2019 08:00 am ET
NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tu
NantKwest, Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced that on Monday, December 2, 2019, it will host a key opinion leader (KOL) meeting in New York City on the current treatment landscapes and unmet medical needs of patients with Merkel cell carcinoma, triple-negative breast cancer, solid tumors and the state-of-the-art treatment in the induction of Immunogenic Cell Death.
Nov 07, 2019 04:15 pm ET
NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019
NantKwest Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced the presentation of results from their Phase 2 trial investigation using aNK, NantKwest’s off-the-shelf natural killer cell-based therapeutic, in combination with N-803, ImmunityBio’s IL-15 superagonist, in patients with advanced refractory metastatic Merkel cell carcinoma (MCC) (NCT03853317) at The 34th Annual Meeting of the Society for
Jun 24, 2019 08:00 am ET
NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors
NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced that the company’s PD-L1 t-haNK investigational new drug application (IND) has cleared FDA review and the program has now transitioned to a first-in-human clinical trial in patients with locally advanced or metastatic solid cancers.
Jun 06, 2019 04:10 pm ET
Cheryl Cohen Appointed to NantKwest’s Board of Directors
NantKwest (Nasdaq:NK) today announced the appointment of Cheryl L. Cohen to the Board of Directors of NantKwes
Jun 04, 2019 08:00 am ET
NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients
Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company today presented a clinical data update in patients who have received off-the-shelf aNK and/or haNK natural killer cell therapy in combination with immunotherapeutic agents in advanced solid tumors. These results demonstrated durable complete responses in 5 out of 35 patients with highly refractory late stage cancers across multiple tumor types.
Jun 04, 2019 07:45 am ET
NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics
NantKwest Inc. (Nasdaq:NK) announced today that its strategic partner Viracta Therapeutics presented updated clinical data on its HDAC inhibitor, nanatinostat (VRx-3996) at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, from May 31st – June 4th, 2019.
Jun 03, 2019 02:50 pm ET
NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients
NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced that the company’s t-haNK investigational new drug application (IND) has cleared FDA review and the program has now transitioned to a first-in-human clinical trial targeting CD19 t-haNK in advanced B-cell lymphoma.
Jun 03, 2019 08:00 am ET
NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference
NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jefferies 2019 Annual Healthcare Conference being held in New York City from June 4th-7th, 2019. The presenta
May 31, 2019 08:00 am ET
NantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting
NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, NantCell Inc., a privately held immunotherapy company, and NantOmics, a privately held molecular diagnostic company, today announced that preclinical and clinical updates will be provided in four abstracts as part of the upcomin
May 01, 2019 08:00 am ET
Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells
Brink Biologics, Inc., a NantKwest, Inc. (Nasdaq:NK) affiliate who serves as exclusively-licensed di
Apr 17, 2019 08:35 am ET
Market Trends Toward New Normal in WageWorks, Maxwell Technologies, Valeritas, NantKwest, Nightstar Therapeutics PLC Sponsored ADR, and Aspen Group — Emerging Consolidated Expectations, Analyst Rating
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of WageWorks, Inc. (NYSE:WAGE), Maxwell Technologies, Inc. (NASDAQ:MXWL),...
Apr 01, 2019 08:00 am ET
NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate
NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the Company has been issued a new patent that further expands the Company’s foundational natural killer cell-therapeutics platform intellectual property estate. This new patent builds upon NantKwest’s extensive existing patent estate and broadens the Company’s established intellectual property combining haNK natural killer cell therapy together with antibody therapy.
Mar 25, 2019 08:00 am ET
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK’s Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy
NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Patrick Soon-Shiong, MD, the company’s Chairman & CEO, on March 2
Mar 18, 2019 05:00 am ET
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit
NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announc
Mar 04, 2019 08:00 am ET
Jan 05, 2019 08:00 am ET
NantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
NantKwest (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases today announced that the company will be hosting an Investor/Analyst Day on Tuesday, January 8, 2019 in San Francisco, California.
Dec 03, 2018 11:00 am ET
NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology
NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, today announced an abstract/poster presentations will be given at the upcoming 60th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA, which runs from December 1-4, 2018.
Nov 07, 2018 05:28 pm ET
NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine Immunotherapy
The recent successes of immunotherapy, such as checkpoint inhibition, have spawned a wave of enthusiasm for immuno-oncology. Unfortunately, only a subset of cancer patients respond to checkpoint inhibitor monotherapy, and many of these checkpoint-responsive patients will eventually relapse. In addition, cellular therapy in the form of CAR-T cells has shown little evidence of effectiveness in solid tumors. Thus, there remains a huge unmet need to address the rising pandemic of cancer with a paradigm shift in treatment. One such opportunity is to
Nov 05, 2018 11:23 pm ET
NantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer Conference
NantKwest (NASDAQ: NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be making multiple presentations associated with the company’s off-the-shelf CD16 targeted NK cell (hanK) and NANT Cancer Vaccine platform at the upcoming Society for Immunotherapy of Cancer (SITC) Conference which runs from November 7 – 11 in Washington D.C.
Oct 23, 2018 08:00 am ET
Investor Expectations to Drive Momentum within Navios Maritime Partners LP, Alliance Data, Eli Lilly, CONVERGEONE HLD, Atkore International Group, and NantKwest — Discovering Underlying Factors of Inf
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Navios Maritime Partners LP (NYSE:NMM), Alliance Data Systems Corporation...
Oct 02, 2018 12:02 pm ET
NantKwest to Present at 2018 Cantor Global Healthcare Conference
NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the upcoming Cantor Global Healthcare Conference on Tuesday, October 2nd in New York City During the conference, company management will be presenting a corporate overview, as well as conducting one-on-one meetings to provide a corporate update, as well as review R&D and clinical activities.
Aug 29, 2018 08:30 am ET
Report: Exploring Fundamental Drivers Behind Navios Maritime Partners LP, CONVERGEONE HLD, Greenbrier Companies, NantKwest, Genpact, and Textainer Group — New Horizons, Emerging Trends, and Upcoming D
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Navios Maritime Partners LP (NYSE:NMM), CONVERGEONE HLD (NASDAQ:CVON),...
Jul 02, 2018 08:10 am ET
Report: Exploring Fundamental Drivers Behind Telecom Argentina, GasLog, National Retail Properties, Appian, Zscaler, and NantKwest — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Telecom Argentina S.A. (NYSE:TEO), GasLog Ltd. (NYSE:GLOG), National...
Jun 19, 2018 05:00 am ET
NantKwest Names Sonja Nelson Chief Financial Officer
NantKwest, Inc. (Nasdaq: NK) today announced the elevation of Sonja Nelson, chief accounting officer for the company, to the role of Chief Financial Officer (CFO).
Jun 05, 2018 01:29 pm ET
NantKwest to Present at Jefferies 2018 Global Healthcare Conference
NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong, Chairman & CEO of NantKwest, will be presenting and conducting one-on-one meetings at the upcoming Jefferies Global Healthcare Conference on Wednesday, June 6, 2018. The presentations will feature a review of the company’s R&D efforts, along with a clinical update provided by company management.
Apr 23, 2018 03:18 pm ET
NantKwest to Present at Upcoming Science & Medicine Conferences
NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at two science and medicine conferences in the months of April and May 2018. The presentations will feature a review of the company’s R&D efforts, along with a clinical update provided by company management.
Mar 13, 2018 07:29 pm ET
NantKwest to Present at Upcoming Investment and Healthcare Conferences
NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be presenting and conducting one-on-one meetings at a number of investment and healthcare conferences in the month of March and April 2018. The presentations and one-on-one discussions will feature a science and business overview, along with a clinical update provided by company management.
Feb 13, 2018 08:00 am ET
Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Glioblastoma
NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, today announced that the first patient has been dosed in a first-in-human, Phase I clinical study in glioblastoma of HER2.taNK, a novel, natural killer cell-based immuno-oncology therapy using CAR technology in patients. The study is being led by Dr. Michael Burger, principal investigator, together with co-principal investigators Profess
Feb 06, 2018 08:25 am ET
New Research Coverage Highlights Atara Biotherapeutics, SPX, Entellus Medical, Columbus McKinnon, NantKwest, and Merrimack Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for
NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), SPX Corporation...
Jan 05, 2018 06:03 pm ET
NantWorks to Present Healthcare and Biotechnology Platforms at 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018 in San Francisco, CA
NantWorks, the parent organization of NantHealth (NASDAQ: NH) and NantKwest (NASDAQ: NK) announced today that Dr. Patrick Soon-Shiong (Chairman, CEO, and Founder) will present the current status of these companies and the overall ecosystem of NantWorks. Specific details will be presented regarding the current status of GPS CancerT
Jan 05, 2018 03:44 am ET
NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting a Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clin
NantKwest (NASDAQ: NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, announced today that the company will be hosting an Investor/Analyst Day on Tuesday, January 9th in San Francisco, California.
Dec 04, 2017 08:00 am ET
NantKwest to Present Data at the 59th Annual Meeting of the American Society of Hematology
NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, today announced an oral presentations will be given at the upcoming 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia on Saturday, December 9, 2017.
Oct 04, 2017 10:30 am ET
Johnson Fistel, Announces Investigations of NantKwest, Inc., K12 Inc., and CytRx Corporation; Long-Term Investors Encouraged to Contact Firm
SAN DIEGO, Oct. 4, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against NantKwest, Inc., K12 Inc., and CytRx Corporation as detailed below:
May 20, 2016 04:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NantKwest, Inc. of Class Action Lawsuit and Upcoming Deadline – NK
NEW YORK, May 20, 2016 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against NantKwest, Inc. (“NantKwest” or the “Company”) (NASDAQ:NK) and certain of its officers.  The class action, filed in United States District Court, Central District of California, and docketed under 16-cv-01947, is on behalf of a class consisting of all persons or entities who purchased NantKwest securities between September 10, 2015 and March 10, 2016 inclusive (the “Class Period”).  This class action seeks to recover damages against Defendants for alleged violations of the ...
May 20, 2016 12:49 pm ET
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of NantKwest, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 23, 2016 - NK
NEW YORK, May 20, 2016 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:
May 18, 2016 12:34 pm ET
INVESTOR ALERT: Rosen Law Firm Reminds NantKwest, Inc. Investors of Important May 23 Deadline In Class Action - NK
NEW YORK, May 18, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of NantKwest, Inc. securities (NASDAQ:NK) from September 10, 2015 through March 10, 2016, both dates inclusive (the “Class Period”) of the important May 23, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for NantKwest investors under the federal securities laws. ...
May 16, 2016 02:48 pm ET
INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Action Lawsuit Involving NantKwest, Inc. and a Lead Plaintiff Deadline of May 23, 2016 - NK
NEW YORK, May 16, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased NantKwest, Inc. (NASDAQ:NK) securities between September 10, 2015 and March 10, 2016....
May 13, 2016 01:45 pm ET
Hagens Berman Advises NantKwest, Inc. (NASDAQ: NK) Investors of Investigation to Expand Class Period to Include IPO and May 23rd Lead Plaintiff Deadline
SAN FRANCISCO, May 13, 2016 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, advises  NantKwest, Inc. (NASDAQ:NK) investors of investigation into expanding the class period to begin on July 27, 2015, the initial public offering (“IPO”) effective date, based on NantKwest’s admitted improper accounting and recent restatements significantly increasing historical net losses, and of May 23, 2016 lead plaintiff deadline....
May 12, 2016 11:17 am ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of NantKwest, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 23, 2016 – NK
NEW YORK, May 12, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:...
May 04, 2016 12:22 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against NantKwest, Inc. (NK) and Lead Plaintiff Deadline: May 23, 2016
NEW YORK, May 4, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against NantKwest, Inc. ("NantKwest" or "the Company") (NASDAQ: NK).  The class action has been filed on behalf of a class consisting of all persons or entities who purchased NantKwest securities between September 10, 2015 through March 10, 2016, inclusive (the "Class Period").
Apr 26, 2016 05:45 pm ET
Investor Alert: The Law Offices of Vincent Wong Notifies Investors of Class Action Lawsuit Involving NantKwest, Inc. and a Lead Plaintiff Deadline of May 23, 2016 - NK
NEW YORK, April 26, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased NantKwest, Inc. (NASDAQ: NK) securities between September 10, 2015 and March 10, 2016.
Apr 15, 2016 02:38 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NantKwest, Inc. of Class Action Lawsuit and Upcoming Deadline - NK
NEW YORK, April 15, 2016 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK) and certain of its officers. The class action, filed in United States District Court, Central District of California, and docketed under 16-cv-01947, is on behalf of a class consisting of all persons or entities who purchased NantKwest securities between September 10, 2015 and March 10, 2016 inclusive (the "Class Period").  This class action seeks to recover damages against Defendants for alleged violations of the fede
Apr 01, 2016 03:00 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of NantKwest, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 23, 2016 -- NK
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK) between September 10, 2015 and March...
Mar 31, 2016 10:11 am ET
Law Offices of Marc S. Henzel Commences Investigation of Companies for Violations of the Federal Securities Laws
MERION, Pa., March 31, 2016 /PRNewswire/ -- The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to shareholders of investigation into the following securities for violations of the Federal Securities Laws:
Mar 24, 2016 05:40 pm ET
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against NantKwest, Inc.
On March 22, 2016, a class action lawsuit was filed in the United States District Court for the Central District of California against NantKwest, Inc. (NASDAQ: NK). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is September 10, 2015 through March 10, 2016.
Mar 24, 2016 10:00 am ET
Shareholder Class Action Filed Against NantKwest, Inc. - NK
RADNOR, Pa., March 24, 2016 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against NantKwest, Inc. (Nasdaq: NK) ("NantKwest" or the "Company") on behalf of purchasers of the Company's securities between September 10, 2015 and March 10, 2016, inclusive (the "Class Period").
Mar 14, 2016 07:28 pm ET
NANTKWEST NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In NantKwest, Inc. To Contact The Firm
NEW YORK, March 14, 2016 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ:NK).
Mar 14, 2016 06:30 pm ET
NantKwest Shareholder (NK) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of NantKwest, Inc.; Encourages Investors to Contact the Firm
SAN DIEGO, March 14, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by NantKwest, Inc. (NASDAQ: NK) and certain of its officers. NantKwest, a biotechnology company, develops immunotherapeutic agents for various clinical conditions.
Mar 14, 2016 06:09 pm ET
Harwood Feffer LLP Announces Investigation of NantKwest, Inc.
NEW YORK, March 14, 2016 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK), concerning whether the board has breached its fiduciary duties to shareholders.
Mar 11, 2016 12:53 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nantkwest, Inc. (NK)
NEW YORK, March 11, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Nantkwest, Inc. ("Nantkwest" or "the Company") (NASDAQ: NK). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at [email protected] or 212-697-6484.
Mar 11, 2016 11:09 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NantKwest, Inc. - NK
NEW YORK, March 11, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.